Loading
Cytovale
Cytovale is pioneering an insightful new way to analyze immune cells and provide timely answers for sepsis and other immune-mediated diseases in under 10 min.
Funding
Every round, secondary, debt facility or acquisition involving Cytovale that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log in